Using statins to reduce liver cancer risk in patients with cirrhosis
Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis
This study is looking at whether taking statins, which are usually used to lower cholesterol, can help prevent liver cancer in people with liver cirrhosis by checking a special marker in their blood that shows their risk of developing cancer.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-10934594 on NIH RePORTER |
What this research studies
This research investigates how statins, commonly used cholesterol-lowering medications, may help prevent hepatocellular carcinoma (HCC) in patients with liver cirrhosis. The study focuses on a specific biomarker, the Prognostic Liver Secretome signature (PLSec), which can indicate the risk of developing HCC. By analyzing serum samples, researchers aim to determine if modulating this biomarker with statins can effectively lower HCC risk. The findings could lead to new preventive strategies for patients at high risk of liver cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with liver cirrhosis who are at risk for developing hepatocellular carcinoma.
Not a fit: Patients without liver cirrhosis or those who do not have a risk of developing hepatocellular carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of liver cancer in patients with cirrhosis, improving their overall prognosis.
How similar studies have performed: Previous studies have shown promising results with statins in reducing HCC risk, indicating that this approach may be effective.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Hoshida, Yujin — Ut Southwestern Medical Center
- Study coordinator: Hoshida, Yujin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.